Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 1
2025 pubmed

Ability of Linezolid to Combat <i>Staphylococcus aureus</i> and <i>Pseudomonas aeruginosa</i> Isolated from Polymicrobial Wound Infections.

Ahmed. Samar A SA; Luu. Vy T VT; Nsuga. Teresa C Oyono TCO; Burgos. Steven E SE; Kreys. Eugene E; Arquiette. Jered J; Lenhard. Justin R JR

Key Findings

  • Linezolid’s killing of Staph aureus is only slightly affected by the presence of Pseudomonas aeruginosa.
  • Clindamycin’s effectiveness against Staph drops more noticeably when Pseudomonas is present.
  • High (supratherapeutic) concentrations of linezolid do not consistently enhance the antimicrobial activity of the host‑defense peptide LL‑37 against Pseudomonas.

Practical Outcomes

  • For DIY health enthusiasts, this research doesn’t offer new protocols or dosage tips for longevity or performance. It mainly informs clinicians that linezolid isn’t a magic booster for natural peptides like LL‑37 in mixed‑bacterial wounds, so it’s not a useful strategy for self‑directed antimicrobial optimization.

Summary

The study looked at how the antibiotic linezolid works against Staph aureus when it’s mixed with Pseudomonas in wound infections, and whether linezolid helps the natural immune peptide LL‑37 kill Pseudomonas. It found that Pseudomonas barely changes linezolid’s ability to kill Staph, and linezolid doesn’t reliably boost LL‑37’s anti‑Pseudomonas effect.

Abstract

<b>Background/Objectives</b>: The optimal therapy for polymicrobial wound infections is poorly defined. We sought to characterize the ability of linezolid to combat mixed cultures of <i>Staphylococcus aureus</i> and <i>Pseudomonas aeruginosa</i>. <b>Methods</b>: The antistaphylococcal activity of linezolid was assessed in 24-h time-killing experiments that used <i>S. aureus</i> and <i>P. aeruginosa</i> isolated from polymicrobial wound infections. Clindamycin was also evaluated as a comparator. A Hill-type mathematical model was used to assess the maximum killing of <i>S. aureus</i> (E<sub>max</sub>). The ability of linezolid to potentiate the activity of host defense peptides against <i>P. aeruginosa</i> was evaluated using LL-37. <b>Results</b>: In the presence of <i>P. aeruginosa</i>, the E<sub>max</sub> of linezolid decreased in 5/9 co-culture experiments and increased in 4/9 co-culture experiments in comparison to linezolid against <i>S. aureus</i> alone. The potency of linezolid was not significantly impacted by the presence of <i>P. aeruginosa</i>. In comparison, the maximal <i>S. aureus</i> killing achieved by clindamycin decreased in eight out of nine experiments, and somewhat paradoxically, the potency increased in nine out of nine experiments. In the host defense peptide assay, the supratherapeutic linezolid concentration of 64 mg/L did not significantly enhance the killing of the LL-37 peptides (<i>p</i> &#x2265; 0.121), but the concentration of linezolid was significantly associated with the killing of one of three <i>P. aeruginosa</i> isolates (<i>p</i> = 0.005). <b>Conclusions</b>: <i>P. aeruginosa</i> had a minimal impact on the antistaphylococcal activity of linezolid in comparison to clindamycin. Linezolid did not exert a consistent ability to enhance the antipseudomonal activity of host defense peptides. These data may help inform antimicrobial selection during polymicrobial wound infections.

Study Information

Provider

pubmed

Year

2025

Date

2025-06-11T00:00:00.000Z

DOI

10.3390/antibiotics14060597

References

38